Celtic targets eye indications, continues fundraising
This article was originally published in Scrip
Executive Summary
Celtic Therapeutics Holdings, the global private equity firm, has made its fourth investment by committing an undisclosed amount for an exclusive option from Resolvyx Pharmaceuticals to acquire and license rights to RX-10045 for all ophthalmic conditions. In connection with the deal, Celtic has bought a note convertible into Resolvyx equity. Meanwhile, Celtic is also putting the final touches to a "substantial" final closing of its current fund.